Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

PLUS vs MLAB: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PLUS Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–3 Matrix Metrics)

PLUS Overall Winner 6-Pillar Tally: PLUS 3 – 3 MLAB Matrix Metrics: PLUS 6 – 3 MLAB

As of Nov 19, 2026, ePlus Inc (PLUS) is the stronger overall head-to-head candidate over Mesa Laboratories Inc (MLAB) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). PLUS carries a Unified Composite Score of 40.6/100 (SELL) at $95.64 (17.2x Forward P/E, 6.8% operating margin), whereas MLAB carries 43.8/100 (HOLD) at $133.41 (24.8x Forward P/E, 10.4% operating margin).

  • Composite vs. Pillar Nuance: While MLAB currently prints a higher short-term Unified Composite Score (43.8/100 HOLD vs. PLUS 40.6/100 SELL), PLUS captures the overall institutional head-to-head verdict (6–3 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (6.8% vs. 10.4% operating margin) and revenue trajectory (+9.7% vs. +2.6% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PLUS vs MLAB
PLUS NASDAQ Head-to-Head Winner
ePlus Inc
Wholesale-Computers & Peripheral Equipment & Software
$95.64
-1.35% 1D
Market Cap $2.5B
TTM Revenue $2.51B
Forward P/E 17.2x
Beta / 30D Vol 0.87β · 57% Vol
Unified Composite Score
40.6 / 100 SELL
Tech 13.0 Fund 39.0 Flow 54.0 Mom 36.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.8% over 20 days), RSI 53
RSI-14: 53.5 · SMA20: $94.02 · SMA50: $93.25
MLAB NASDAQ
Mesa Laboratories Inc
Industrial Instruments For Measurement, Display, And Control
$133.41
-3.19% 1D
Market Cap $774.6M
TTM Revenue $251M
Forward P/E 24.8x
Beta / 30D Vol 1.12β · 53% Vol
Unified Composite Score
43.8 / 100 HOLD
Tech 25.0 Fund 39.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.8% over 20 days), RSI 53
RSI-14: 52.5 · SMA20: $130.96 · SMA50: $129.90

6-Pillar Scorecard Institutional Category Breakdown (PLUS 3 – 3 MLAB)

Columns: Metric · PLUS · MLAB
1. Valuation Multiples PLUS
Forward P/E 17.2x 24.8x
Trailing P/E 20.3x 118.8x
PEG Ratio 1.11x N/M
EV / Revenue 0.9x 3.1x
2. Growth & Scale PLUS
Revenue Growth (YoY) +9.7% +2.6%
Earnings Growth (YoY) +18.0% +67.0%
TTM Revenue (USD) $2.51B $251M
Market Cap $2.5B $774.6M
3. Profitability & Quality MLAB
Gross Margin 25.2% 64.8%
Operating Margin 6.8% 10.4%
Net Profit Margin 5.0% 2.6%
Return on Equity (ROE) 11.6% 3.6%
4. Balance Sheet & Cash Flow MLAB
Cash Generation (TTM) $32M $49M EBITDA
Cash Flow Margin 1.3% 19.4% EBITDA Mgn
Net Cash / Leverage $242M Net Cash $34.66 Book/Sh · 3.6% ROE
Dividend Yield 1.09% 0.48%
5. Options & Positioning PLUS
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 56.1% (26th %ile) N/A (N/A)
Put/Call OI Skew 0.53x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat MLAB
OpEx & R&D Intensity 18.4% of Rev ($461M) 54.4% of Rev ($137M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Software - Application Operator Scientific & Technical Instruments Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PLUS (6) vs MLAB (3)
Institutional Metric PLUS MLAB Criterion Row Edge
Market Capitalization
Scale
$2.5B $774.6M Larger Scale PLUS
Trailing P/E Ratio
Valuation
20.3x 118.8x Lower Multiple PLUS
Forward P/E Ratio
Valuation
17.2x 24.8x Lower Multiple PLUS
Revenue Growth (YoY)
Growth
+9.7% +2.6% Higher Growth PLUS
Operating Margin (TTM)
Profitability
6.8% 10.4% Higher Margin MLAB
Net Profit Margin
Profitability
5.0% 2.6% Higher Margin PLUS
Return on Equity (ROE)
Capital Efficiency
11.6% 3.6% Higher ROE PLUS
52-Week Range Position
Momentum
85% ($73–$100) 85% ($70–$144) Stronger Trend Tie
Beta / 30D Volatility
Risk Regime
0.87β · 57% Vol 1.12β · 53% Vol Lower Realized Risk MLAB
Unified Institutional Score
Composite Signal
40.6 / 100 (SELL) 43.8 / 100 (HOLD) Higher Composite MLAB
Trailing 12M Revenue (USD)
Operating Scale
$2.51B $251M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
25.2% 64.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.11x PEG · 0.9x EV/Rev N/M PEG · 3.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$32M ($242M Net Cash) $49M EBITDA ($34.66 Book/Sh · 3.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MLAB +1.67 pp
PLUS: +1.59% · MLAB: +3.26%
3M Horizon PLUS +3.19 pp
PLUS: +10.12% · MLAB: +6.93%
6M Horizon MLAB +5.82 pp
PLUS: +16.45% · MLAB: +22.27%
1Y Horizon MLAB +80.57 pp
PLUS: +8.37% · MLAB: +88.94%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PLUS vs MLAB. Trailing 12-month operating profitability (PLUS 6.8% vs MLAB 10.4%) and valuation multiples (PLUS 17.2x vs MLAB 24.8x Forward P/E) are benchmarked directly in Pillar 4 below.

PLUS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.51B
Gross Margin25.2%
Op. Margin6.8%
ROE / Fwd P/E11.6% · 17.2x
MLAB ADR TTM Benchmark FX-Normalized USD
TTM Revenue$251M
Gross Margin64.8%
Op. Margin10.4%
ROE / Fwd P/E3.6% · 24.8x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PLUS CONSOLIDATION
135d in phase · OBV NEUTRAL
Current IV 56.1%
IV Percentile 26th %ile
Put/Call OI Skew 0.53x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact PLUS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MLAB UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MLAB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PLUS Moat Profile Cyclical / Execution-Driven Positioning
Software - Application Operator
Competes within the Software - Application value chain with $2.5B market capitalization and 6.8% operating margin.
OpEx & R&D Reinvestment 18.4% of Rev ($461M)
90D Engineering Disclosures 0 Published
MLAB Moat Profile Cyclical / Execution-Driven Positioning
Scientific & Technical Instruments Operator
Competes within the Scientific & Technical Instruments value chain with $774.6M market capitalization and 10.4% operating margin.
OpEx & R&D Reinvestment 54.4% of Rev ($137M)
90D Engineering Disclosures 0 Published

Investor FAQ PLUS vs MLAB Key Questions & Quantitative Answers

As of Nov 19, 2026, ePlus Inc (PLUS) is the stronger overall head-to-head candidate over Mesa Laboratories Inc (MLAB) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). PLUS carries a Unified Composite Score of 40.6/100 (SELL) at $95.64 (17.2x Forward P/E, 6.8% operating margin), whereas MLAB carries 43.8/100 (HOLD) at $133.41 (24.8x Forward P/E, 10.4% operating margin). Composite vs. Pillar Nuance: While MLAB currently prints a higher short-term Unified Composite Score (43.8/100 HOLD vs. PLUS 40.6/100 SELL), PLUS captures the overall institutional head-to-head verdict (6–3 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (6.8% vs. 10.4% operating margin) and revenue trajectory (+9.7% vs. +2.6% YoY).

PLUS leads the Growth & Scale pillar: PLUS posts +9.7% YoY revenue growth and +18.0% YoY earnings growth on $2.51B TTM revenue (25.2% gross margin, 6.8% operating margin), compared with MLAB at +2.6% YoY revenue growth and +67.0% YoY earnings growth on $251M TTM revenue (64.8% gross margin, 10.4% operating margin). On trailing 12-month operating scale, PLUS generates $2.51B in USD-normalized revenue versus $251M for MLAB. In operating R&D and SG&A reinvestment, PLUS deploys 18.4% of Rev ($461M) (0 90-day corporate R&D disclosures) versus 54.4% of Rev ($137M) (0 disclosures) for MLAB.

PLUS screens cheaper on headline valuation multiples. PLUS trades at 17.2x Forward P/E, 20.3x Trailing P/E, 1.11x PEG, and 0.9x EV/Revenue (1.3% FCF margin), whereas MLAB trades at 24.8x Forward P/E, 118.8x Trailing P/E, N/M PEG, and 3.1x EV/Revenue (19.4% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PLUS (11.6% ROE) versus MLAB (3.6% ROE) capital efficiency.

In options market volatility and institutional positioning, PLUS carries 56.1% implied volatility (26th %ile, Balanced (25th–60th %ile)), a 0.53x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.87β · 57% Vol realized risk). By comparison, MLAB carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.12β · 53% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.